Home

disease management

Read time: 3 min

Satellite symposium

Understanding patient preferences to increase treatment adherence in schizophrenia

Schizophrenia is a debilitating and lifelong mental health disorder characterized by disorganized...

Read time: 5 min

Satellite symposium

Why should we care about anhedonia in major depressive disorder?

There continues to be unmet needs in the treatment of patients with major depressive disorder (MDD...

Read time: 4 min

Satellite symposium

The importance of patient life engagement in schizophrenia

At the 2023 ECNP Congress in Barcelona, Spain (7−10th Oct), two symposia explored the...

Read time: 4 min

Attributing a causal role to migraine “triggers”: is greater caution needed?

Smart phones and electronic diaries increase our ability to track behavioral and environmental...

Patients should be aware that cognitive dysfunction can delay recovery in major depressive disorder

At ECNP, Dr Charlotte Emborg discussed how people with major depressive disorder (MDD) often have...

Read time: 4 min

Congress highlights

Salivary calcitonin gene-related peptide as a potential biomarker for migraine

Levels of calcitonin gene-related peptide (CGRP) are higher in patients with migraine in the...

Early schizophrenia intervention positively benefits functionality and reduces number of lifetime relapses

Professor Leslie Citrome sat down at ECNP 2022 to discuss how early intervention is critical for...

Neurotoriun

Neurotorium is your new point of reference for educational content on psychiatry, neurology, and neuroscience.

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind MENA Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind Greece Continue to Progress in Mind South East Asia Continue to Progress in Mind Middle East & Africa Continue to Progress in Mind United Kingdom Continue to Progress in Mind Sweden Continue to Progress in Mind Norge Continue to Progress in Mind Denmark Continue to Progress in Mind Japan RC Continue to Progress in Mind България Continue to Progress in Mind Israel Continue to Progress in Mind Sweden Continue to Progress in Mind Finland Continue to Progress in Mind Ukraine Continue to Progress in Mind Belgium & Luxembourg Continue to Progress in Mind Switzerland Continue to Progress in Mind Germany Continue to Progress in Mind Austria

You are leaving Progress in Mind

Continue to

Cancel

Progress in Mind Belux

Accept Cancel

Login as a registered health care professional

Please enter your email to continue

Register as a health care professional

Please enter your email to continue

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intended for health care professionals.

All the information included in the Website is related to diseases, investigations and existing or potential treatment options and, therefore, directed to health professionals . The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country